JAKi Cibinqo owns strengths in dosage adjustments
By Jung, Sae-Im | translator Kim, Jung-Ju
23.05.15 12:03:04
가나다라
0
Pfizer’s JAK inhibitor to likely receive reimbursement for atopic dermatitis within the first half of the year
Dose can be adjusted according to treatment progress... frequency of acne side effects low
Shows effect after switching to Cibinqo depending on whether a patient shows an effect with Dupixent...”can serve as for reimbursement extensions”
Pfizer's JAK inhibitor ‘Cibinqo (abrocitinib)' has embarked on a full-fledged journey to expand its prescriptions. After landing in major general hospitals at the end of last year, the drug is likely to be registered for reimbursement within the first half of this year.
Cibinqo is a Janus kinase 1 (JAK1) inhibitor approved by the Ministry of Food and Drug Safety in November 2021. It is the 4th JAK inhibitor introduced to Korea and the second JAK inhibitor drug introduced by Pfizer after Xeljanz. Unlike Xeljanz, which is only used for ulcerative colitis, Cibinqo is used to treat severe atopic dermatitis.
Treatment options have increased significantly for severe atopic dermatitis star
Jung, Sae-Im (same@dailypharm.com)
If you want to see the full article, please JOIN US (click)